Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 78Gastrointestinal 7Genitourinary 6Breast 6Thoracic 5Dermatologic 5Sarcoma 3Other hematologic neoplasm 2Head & Neck 2CNS 2Plasma cell 1NET 1Lymphoid 1Endocrine 1Classical hematology 1

Conditions

Neuroendocrine Tumors 51Gastro-enteropancreatic neuroendocrine tumor 10Carcinoma, Neuroendocrine 8Small Cell Lung Carcinoma 6Adenoma, Islet Cell 6Colorectal Neoplasms 4Cholangiocarcinoma 3Carcinoma, Merkel Cell 3Carcinoma, Hepatocellular 3Carcinoid Tumor 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Salivary Gland Neoplasms 2Pheochromocytoma 2Paraganglioma 2Pancreatic Neoplasms 2Neoplasms, Unknown Primary 2Neoplasms 2Lung Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Medullary 2Brain Neoplasms 2Biliary Tract Neoplasms 2Vulvar Neoplasms 1Vipoma 1Urinary Bladder Neoplasms 1Thyroid cancer, medullary 1Thyroid Cancer, Papillary 1Thymus Neoplasms 1Testicular Neoplasms 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Fallopian Tube Neoplasms × NET × Clear all
NCT05199272 2024-11-15

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

23andMe, Inc.

Phase 1/2 Active not recruiting
141 enrolled
EndocrineGenitourinaryGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡